SCHEMBL334267

SCHEMBL334267

CCOC(=O)c1cccc(OCCC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.70
PPARD Q03181 8/20 0.70
PPARA Q07869 6/20 0.70
PCSK9 Q8NBP7 2/20 0.55
MAPT P10636 6/20 0.49
TP53 P04637 5/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP2D6 P10635 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.46
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10219914 0.94 PPARG (0.61) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL10219848 0.92 PPARG (0.59) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL10219861 0.91 PPARG (0.69) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL10219920 0.90 PPARG (0.57) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL10219894 0.90 PCSK9 (0.65) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL334676 0.89 PPARD (0.79) PPARGPPARDPPARAMAPTTP53
SCHEMBL10219858 0.87 PPARD (0.81) PPARGPPARDPPARAMAPTTP53
SCHEMBL10219879 0.87 PPARD (0.73) PPARGPPARDPPARAPCSK9TP53
SCHEMBL10219880 0.87 PPARD (0.59) PPARGPPARDPPARAPCSK9MAPT
SCHEMBL10219841 0.87 PCSK9 (0.56) PPARGPPARDPPARAPCSK9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG PPARG 3/4885PPARD 1/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.